Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma Trading ADFRA:6YH +0.74%82 Return-on-Tangible-Equity is 38.49% as of Mar. 2026, which is 10% below its 10-year median of 42.80. GuruFocus rates FRA:6YH with a GF Score™ of 82/100 and a GF Value™ of €7.38. The stock has 2 warning signs investors should review. Among 111 Medical Distribution companies, Sopharma Trading AD ranks better than 80.18% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sopharma Trading AD's annualized net income for the quarter that ended in Mar. 2026 was €33 Mil. Sopharma Trading AD's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €87 Mil. Therefore, Sopharma Trading AD's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 38.49%.
The historical rank and industry rank for Sopharma Trading AD's Return-on-Tangible-Equity or its related term are showing as below:
FRA:6YH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 19.25 Med: 42.8 Max: 57.4
Current: 33.22
During the past 13 years, Sopharma Trading AD's highest Return-on-Tangible-Equity was 57.40%. The lowest was 19.25%. And the median was 42.80%.
FRA:6YH's Return-on-Tangible-Equity is ranked better than 80.18% of 111
companies
in the Medical Distribution industry
Industry Median: 8.81
vs FRA:6YH: 33.22
Sopharma Trading AD (FRA:6YH) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sopharma Trading AD Return-on-Tangible-Equity Related Terms
Sopharma Trading AD Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma Trading AD Return-on-Tangible-Equity Chart
FRA:6YH vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Sopharma Trading AD's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 38.49% mean?
Sopharma Trading AD (FRA:6YH) has a Return-on-Tangible-Equity of 38.49% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sopharma Trading AD and its competitors. This is 10% below median its historical median of 42.80. Over the past decade, Sopharma Trading AD's Return-on-Tangible-Equity has ranged from 19.25 to 57.40. According to the industry distribution chart, Sopharma Trading AD ranks #22 out of 111 companies in the Medical Distribution industry, placing it in the top 19.8%.
Is Sopharma Trading AD's Return-on-Tangible-Equity too high?
Sopharma Trading AD's current Return-on-Tangible-Equity of 38.49% is 10% below median its 10-year median of 42.80. Over the past 10 years, this metric has ranged from a low of 19.25 to a high of 57.40. The Medical Distribution industry median Return-on-Tangible-Equity is 8.81. Sopharma Trading AD's value of 38.49% is 336.9% above this industry median. Based on the distribution chart, Sopharma Trading AD ranks #22 out of 111 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma Trading AD has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #22 out of 111 companies for Return-on-Tangible-Equity. This places Sopharma Trading AD in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 8.81. Sopharma Trading AD's value of 38.49% is 336.9% above this benchmark. Historically, Sopharma Trading AD's own Return-on-Tangible-Equity has ranged from 19.25 to 57.40 over the past decade. While the company's 10-year median is 42.80 vs. the industry median of 8.81, Sopharma Trading AD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.81, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current Return-on-Tangible-Equity of 38.49% is 336.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current Return-on-Tangible-Equity is 38.49%, which is 10% below median its own 10-year median of 42.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Sopharma Trading AD (FRA:6YH) has a current Return-on-Tangible-Equity of 38.49%. The stock's GF Value™ is €7.38, compared to a current price of €2.74 — trading 62.9% below its estimated fair value. The current Return-on-Tangible-Equity is 38.49%, which is 10% below median its 10-year median of 42.80 and 336.9% above the Medical Distribution industry median of 8.81. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sopharma Trading AD (FRA:6YH), the current Return-on-Tangible-Equity is 38.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (FRA:6YH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.74 is trading 62.9% below its estimated GF Value™ of €7.38.
Key valuation signals for FRA:6YH:
Return-on-Tangible-Equity: 38.49% (10% below median its 10-year median of 42.80)
GF Value™: €7.38 vs. price of €2.74 (62.9% below fair value)
Industry Position: 336.9% above the Medical Distribution median (#22 of 111)
No single metric tells the full story. See the FRA:6YH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score
Get the complete analysis for FRA:6YH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YH has been successfully added to your 
